Up responders (increased gene expression post-treatment) are characterized by enrichment in proneural glioblastoma stem cells and differentiated neoplastic cells, whereas down responders (decreased gene expression post-treatment) undergo mesenchymal transition, suggesting the potential for subtype-specific therapeutic strategies.103 The transition towards a mesenchymal phenotype is accompanied by increased interactions with myeloid cells104 and increased T-cell abundance associated with hypermutation status, a process regulated by activator protein 1.105. Here, JUN is linked to glioblastoma.